23andMe

  • Innovation in genomics and the future of medtech  Crunch Network

    Innovation in genomics and the future of medtech 

    The field of medicine is in the process of being profoundly transformed by new technologies; much of this transformation comes from exciting advances in genomics. Although genomics is relatively unknown to the general public, innovations in the field have started to make headlines: Genetic testing startup 23andMe, the “gene editing” technology CRISPR and the ambitious 100,000… Read More

  • Bio

    13 women leading the life sciences movement in Silicon Valley

    Breakthroughs in genetic engineering, 3D printing, cloud-based science experiments, A.I. and machine learning technology have created a weird and cool new kind of cutting-edge biotech that goes beyond pharma into what just a few decades ago seemed like magical thinking. And women are leading the charge in this brave new world, especially in Silicon Valley. While there are plenty of women… Read More

  • 23andMe and Women’s Health Startup Celmatix Combine Forces To Research Genes Affecting Infertility

    23andMe and Women’s Health Startup Celmatix Combine Forces To Research Genes Affecting Infertility

    Humans have been having humans for hundreds of thousands of years as part of our genetic drive so it seems counter-Darwinian that some genes might work against our ability to make a baby. But that is exactly what certain genes might be doing, according to women’s health startup Celmatix, and they are now working with 23andMe to hopefully figure out why. Celmatix tries to take the… Read More

  • Bio
    The Evolution Of The Biohacking Ecosystem Crunch Network

    The Evolution Of The Biohacking Ecosystem

    Silicon Valley efforts in the biology and health domains have recently seen increased public interest because of the questions around the legitimacy of Theranos’ technology and medical claims and the recent FDA approvals for a number of 23andMe’s genetic screens. These data points are just two of the most visible examples of a broad ecosystem of companies and startups in Silicon… Read More

  • FDA Clears 23andMe For Health and Carrier Status Testing

    FDA Clears 23andMe For Health and Carrier Status Testing

    Things are looking up for 23andMe. Right off a fresh $115 million cash infusion, the Food and Drug Administration is giving the direct-to-consumer DNA company the green light to include health and carrier status, along with ancestry reports. This was not the scenario two years ago when the FDA put a moratorium on 23andMe’s ability to provide any health information associated with… Read More

  • WellPath Integrates With 23andMe, Fitbit To Customize Your Daily Supplements

    WellPath Integrates With 23andMe, Fitbit To Customize Your Daily Supplements

    These days, you can get a subscription box for just about anything. And today, that includes customized nutritional supplements. WellPath, a company that puts together customized packages of monthly nutritional supplements tailored to your specific body, has today announced integrations with 23andMe and Fitbit to get even more granular with the way that suggest products. Originally, WellPath… Read More

  • Warburg Pincus, Illumina & Sutter Hill Launch New Genomics Co. Helix With $100M

    Warburg Pincus, Illumina & Sutter Hill Launch New Genomics Co. Helix With $100M

    Based in San Francisco, Helix is aiming to be a central repository for personalized genetic information and provide a marketplace for applications potentially like the ones developed in Illumina’s genome-based accelerator program. Read More

  • We Asked Rock Health Founder Halle Tecco About The Future Of Digital Medicine

    Health technology is becoming a big topic in 2015. We’re seeing wearable technology that can automatically upload our health data to the cloud, cellphones are becoming tools to connect us to the doctor’s office, a Google moonshot project detects cancer on an app and 23andMe has received FDA approval for at least one genetic test of a rare disease. This is now a multi-billion… Read More

  • Genomics Needs A Killer App Crunch Network

    Genomics Needs A Killer App

    Genomics has undergone a major shift in the last year. The drop in price in the past decade from $3B to $1K to sequence a genome is the 10X force likely to cause an inflection point in a number of health-related industries. But despite the price, right now genomics is a niche product in large part used in and promoted by academia. Read More

  1. 1
  2. 2
  3. ...